At the first annual PSMA Conference, Dr. Amar Kishan from the University of California, Los Angeles discusses how he believes PSMA treatment will advance in the future, as well as new research presented at the conference.
Dr. Amar Kishan on What’s in Store for the Future of PSMA Treatment
By Amar Kishan, MD - Last Updated: January 24, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.